Advanced Enzyme Technologies — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Peer selection

Peers are selected from the same Branded generics & specialty pharma industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Advanced Enzyme Technologies ADVENZYMES · you	₹3,149 Cr	21.7×	2.2×	10.4×	10.3%	22.6%	11.3%
Sector median	—	30.1×	4.9×	29.0×	16.4%	20.9%	18.8%
Acutaas Chemicals ACUTAAS	₹26,189 Cr	73.8×	15.8×	54.5×	21.5%	26.6%	29.5%
Pfizer PFIZER	₹21,129 Cr	29.1×	5.0×	24.7×	17.2%	28.7%	1.3%
Piramal Pharma PPLPHARMA	₹19,898 Cr	—	2.7×	33.4×	-4.0%	-3.7%	7.8%
Eris Lifesciences ERIS	₹19,020 Cr	30.2×	4.8×	18.1×	15.9%	19.8%	22.9%
Onesource Specialty Pharma ONESOURCE	₹18,447 Cr	—	3.4×	64.6×	-1.3%	-5.2%	232.4%
AstraZeneca Pharma India Limited ASTRAZEN	₹17,766 Cr	94.7×	20.4×	67.4×	21.5%	8.2%	31.4%
Alivus Life Sciences Limited ALIVUS	₹16,540 Cr	29.9×	5.1×	20.4×	16.9%	22.1%	5.7%
NATCO Pharma NATCOPHARM	₹15,503 Cr	11.0×	1.7×	10.9×	15.4%	34.8%	14.6%

Peer comparison verdict

Advanced trades at a discount to sector peers on P/E (21.7× vs median 30.1×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.

How the peer fair value is calculated

Three valuation methods are weighted by sector. Each gives a fair value based on how sector peers are currently priced.

Method breakdown

40% weight · 5 peers

Sector median PE29.9×

Fair value via PE₹389

20% weight · 8 peers

Sector median PB4.9×

Fair value via PB₹632

EV/EBITDA

40% weight · 8 peers

Sector median EV/EBITDA29.0×

Fair value via EV/EBITDA₹788

Blended peer fair value₹597

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.